Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Rating)'s stock price fell 2.6% on Tuesday . The company traded as low as $0.28 and last traded at $0.29. 134,907 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 872,656 shares. The stock had previously closed at $0.29.
Marker Therapeutics Trading Down 2.6 %
The stock has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.35. The firm has a market capitalization of $23.83 million, a P/E ratio of -0.66 and a beta of 1.03.
Get Marker Therapeutics alerts:Institutional Investors Weigh In On Marker Therapeutics
Large investors have recently made changes to their positions in the company. Raymond James & Associates bought a new stake in shares of Marker Therapeutics during the 3rd quarter valued at about $35,000. Matrix Asset Advisors Inc. NY grew its stake in shares of Marker Therapeutics by 66.7% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 250,000 shares of the company's stock valued at $83,000 after acquiring an additional 100,000 shares during the period. Finally, AR Asset Management Inc. grew its stake in shares of Marker Therapeutics by 290.2% during the 1st quarter. AR Asset Management Inc. now owns 279,000 shares of the company's stock valued at $123,000 after acquiring an additional 207,500 shares during the period. 26.62% of the stock is currently owned by institutional investors.
Marker Therapeutics Company Profile
(Get Rating)Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens.
Further Reading
- Get a free copy of the StockNews.com research report on Marker Therapeutics (MRKR)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.